Thierry Van Nieuwenhove, CEO, Quotient Sciences
Advertisement
Articles by Thierry Van Nieuwenhove, CEO, Quotient Sciences
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
FDA Clears IND for Biolojic’s BD200, the First AI-Designed Multibody ADC to Enter Clinical Trials
4
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
5